TG Therapeutics (TGTX) shares soared on Aug 21 as speculation emerged that the biotech firm could be the target of a potential takeover. Investors cheered TGTX following an “uncooked” alert from Betaville, suggesting a U.S. biopharma company with a market cap between $20 billion and $40 billion may be interested in acquiring TG Therapeutics.
Following the meteoric rally on Friday, TG Therapeutics stock is up about 85% versus the start of this year.